| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 8.16 | 0.50 (+6.53%) | 1.68 - 9.98 | 6.0 million (Above Avg) |
Market data as of 11:52AM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 8.04 |
|---|---|
| Previous Close | 7.66 |
| Day's Range | 8.02 - 8.50 |
| Market Cap | 666.8M |
| Avg Volume (10 Day) | 2.4M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.23 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals
PR Newswire - Monday 06/17/2013 8:00 AM ET
Keryx Biopharmaceuticals, Inc. Announces Zerenex™ Phase 3 Data Presented at the 2013 World Congress of Nephrology
PR Newswire - Monday 06/03/2013 8:30 AM ET
| KERX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 40.00% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 89.42 |
| Company | Last | Change |
|---|---|---|
| Intercept Pharmaceuticals Inc | 36.31 | +10.00% |
| KYTHERA Biopharmaceuticals Inc | 25.36 | -0.70% |
| Astex Pharmaceuticals Inc | 4.92 | +1.03% |
| Raptor Pharmaceutical Corp | 8.02 | +2.43% |
| Neurocrine Biosciences Inc | 13.00 | +2.36% |
Data is delayed by at least 15 min.